# Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

Study · id `cardio:ct-nct03767543` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03767543](<https://clinicaltrials.gov/study/NCT03767543>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03767543

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 265 participants.

## Technical summary

Registry record NCT03767543. Randomized; no masking; primary purpose treatment. Start 2019-03-11 (actual); primary completion 2020-10-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 265 participants (enrolled count; ClinicalTrials.gov record NCT03767543, source copy `cardio:ctgov-nct03767543-2022-04-25`, retrieved 2026-10-26)
- Started: 2019-03-11 (actual) (ClinicalTrials.gov record NCT03767543, source copy `cardio:ctgov-nct03767543-2022-04-25`, retrieved 2026-10-26)
- Primary completion: 2020-10-23 (actual) (ClinicalTrials.gov record NCT03767543, source copy `cardio:ctgov-nct03767543-2022-04-25`, retrieved 2026-10-26)
- Completion: 2020-10-23 (actual) (ClinicalTrials.gov record NCT03767543, source copy `cardio:ctgov-nct03767543-2022-04-25`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT03767543, source copy `cardio:ctgov-nct03767543-2022-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03767543-2022-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
- Acronym: LixilanOne CAN
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial (`cardio:pubmed-35670659`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e1b90688aacc4151d250290b109e8629cdd219c583d573f93309251c1965006f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
